Sort By
-
John Kyung Lee
A highly aggressive subtype of treatment-resistant prostate..
John Kyung Lee
2015 Lori Milken–PCF Young Investigator
John Kyung Lee, MD:
University of Washington
Mentor:
Owen Witte, MD
Proposal Title:
Therapeutic Targeting of N-Myc-Driven Human Small Cell Neuroendocrine Prostate Cancer
-
Vishal Kothari
New therapeutic targets and prognostic biomarkers for..
Vishal Kothari
2015 Gerry Lenfest–PCF Young Investigator
Vishal Kothari, PhD:
University of Michigan
Mentors:
Arul Chinnaiyan, MD, PhD; Felix Feng, MD
Proposal Title:
Investigating DNAPK as a Therapeutic Target and a Prognostic Biomarker in Castration-Resistant Prostate Cancer
-
Won Kim
The emergence of treatment-resistant prostate cancer (CRPC)..
Won Kim
2015 Dendreon Pharmaceuticals–PCF Young Investigator
Won Kim, MD:
University of California, San Francisco
Mentors:
Charles Ryan, MD; Eric Small, MD
Proposal Title:
Dissecting Variant Androgen Signaling Phenotypes to Guide Treatment Selection in Abiraterone Acetate and Enzalutamide-Resistant Prostate Cancer
-
Joseph Ippolito
Metabolic oxidative phosphorylation (OXPHOS) is a biochemical..
Joseph Ippolito
2015 Victoria & Vinny Smith, Eustace Wolfington,
and Ali & Joe Torre–PCF Young InvestigatorJoseph Ippolito, MD, PhD:
Washington University School of Medicine in St. Louis
Mentors:
Jeffrey Arbeit, MD; Farrokh Dehdashti, MD
Proposal Title:
Characterizing and Imaging Metabolic Symbiosis in Castrate- Resistant Prostate Cancer
-
Howard Scher
Cell signaling in cancer causes uncontrolled cell..
Howard Scher
Howard Scher, MD –:
Memorial Sloan-Kettering Cancer Center
Development of Combined Inhibition of AR and PI3K Signaling as a Therapeutic Strategy for Advanced Prostate CancerCo-Investigators:
Charles Sawyers, MD; Brett Carver, MD; Neal Rosen, MD, PhD
-
Amanda Hargrove
Long noncoding RNAs (lncRNAs) play a critical..
Amanda Hargrove
2015 Brent Nicklas–PCF Young Investigator
Amanda Hargrove, PhD:
Duke University
Mentors:
Hashim Al-Hashimi, PhD; Peter Dervan, PhD
Proposal Title:
Targeting the lncRNA SChLAP1 in Aggressive Prostate Cancer by the Assembly of Multivalent Small Molecule Inhibitor
-
Justin Drake
Men with progressive metastatic prostate cancer are..
Justin Drake
Justin Drake, PhD:
Rutgers University Cancer Institute of New Jersey
Mentor:
Robert DiPaola, MD
Proposal Title:
Elucidating Kinase Activation Pathways in Advanced Prostate Cancer
2015 Adrianne & Jerry Cohen, Larry Gagosian, and Pablo Legorreta–PCF Young Investigator
-
Martin Sanda
Dr. Sanda and his cross-disciplinary team of..
Martin Sanda
Martin Sanda, MD –:
Beth Israel Deaconess Medical Center
Nanoparticle-Targeted Peptide Vaccines for Prostate Cancer: The Harvard – Hopkins – Carolina ConsortiumCo-Investigators:
Joseph M DeSimone, PhD; Simon M Arredouani, PhD; Charles Drake, MD, PhD
-
William G. Nelson
One of the causes for the initiation..
William G. Nelson
William G. Nelson, MD, PhD – :
Johns Hopkins Medicine
Induction of Synthetic Lethality with Epigenetic therapy (ISLET) for Systemic Treatment of Prostate CancerCo-Investigators:
Srinivasan Yegnasubramanian, MD, PhD; Jun O. Liu, PhD; Stephen B. Baylin, MD; Michael A. Carducci, MD; Martin J. Aryee, PhD
-
Christopher J. Logothetis
Despite initial response, most prostate cancers will..
Christopher J. Logothetis
Christopher J. Logothetis, MD –:
The University of Texas MD Anderson Cancer Center Mechanisms of Resistance to Androgen Biosynthesis Inhibition in Castration-Resistant Prostate Cancer Bone Metastases
Co-Investigators:
Gary Gallick, PhD; Sankar Maity, PhD; Randall Millikan, MD, PhD; Mark Bedford, PhD; Eleni Efstathiou, MD, PhD
-
Heather Cheng
Although family history is well-established as a..
Heather Cheng
Heather Cheng, MD, PhD:
University of Washington
Mentor:
Peter Nelson, MD
Proposal Title:
Identifying High-Penetrance Prostate Cancer Risk Genes: Leveraging Families for Next Generation Discovery and Prevention
2015 Kelsey Dickson–PCF Young Investigator
-
Dr. Glenn Liu
As prostate cancer advances and spreads, it..
Dr. Glenn Liu
Dr. Glenn Liu, MD –:
UW Carbone Cancer Center Imaging Biomarkers of Treatment Response Using NaF PET/CT Imaging: a Prostate Cancer Clinical Trials Consortium (PCCTC) Effort
Co-Investigators:
Michael Morris; William Dahut, MD; Steven Larson, MD; Peter Choyke, MD; Robert Jeraj, PhD
-
Philip G. Febbo
Drs. Febbo and Higano propose a phase..
Philip G. Febbo
Philip G. Febbo, MD –:
University of California, San Francisco
Understanding the Clinical and Radiological Impact of XL184 through Treatment ScienceCo-Investigators:
Celestia Higano, MD, Beatrice Knutson, PhD, Peter Nelson, MD, Edwin Posadas, MD, Ravi Salgia, MD, Evan Yu, MD
-
Leland W.K. Chung
There are very few effective medications for..
Leland W.K. Chung
Leland W.K . Chung, PhD –:
Cedars-Sinai Medical Center
Targeting Cell Death Programs in the Tumor and its MicroenvironmentCo-Investigators:
Edwin Posadas, MD; Neil Bhowmick, PhD; Hyung L Kim, MD;
Andre Rogatko, PhD; Beatrice Knudsen, MD, PhD; Stuart Holden, MD; Mahul B. Amin, MD; Martin Gleave, MD; Michael Freeman, PhD; Daqing Wu, PhD; Matthew Bui, MD
